ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
9.25
+0.96 (11.58%)
At close: Mar 27, 2026, 4:00 PM EDT
9.40
+0.15 (1.62%)
After-hours: Mar 27, 2026, 7:59 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for ADMA Biologics stock has a target of 32, which predicts a 245.95% increase from the current stock price of 9.25.
Price Target: $32 (+245.95%)
Analyst Consensus: Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2026 |
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +245.95% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +170.27% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +181.08% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +170.27% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
650.25M
from 510.17M
Increased by 27.46%
Revenue Next Year
794.02M
from 650.25M
Increased by 22.11%
EPS This Year
0.92
from 0.60
Increased by 53.85%
EPS Next Year
1.20
from 0.92
Increased by 30.02%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 672.0M | 820.5M | |||
| Avg | 650.3M | 794.0M | |||
| Low | 622.3M | 760.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 31.7% | 26.2% | |||
| Avg | 27.5% | 22.1% | |||
| Low | 22.0% | 16.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.99 | 1.32 | |||
| Avg | 0.92 | 1.20 | |||
| Low | 0.85 | 1.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 64.5% | 43.3% | |||
| Avg | 53.9% | 30.0% | |||
| Low | 42.1% | 16.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.